Introduction: Statin, the first-line treatment for dyslipidaemia, may have suboptimal adherence due to its associated muscle adverse events. These data, however, remain limited. Aim: To determine the association of serum creatine kinase (CK) and SLCO1B1 rs4363657 polymorphism with statin-associated muscle adverse events (SAMAE) among dyslipidaemia participants. Methods: This was a prospective cohort study at government health clinics involving newly diagnosed adults with dyslipidaemia. SAMAE were recorded based on the patient's complaint after a month on statin. CK was taken at baseline and follow-up. Genetic profiling was performed for SLCO1B1 rs4363657 polymorphism. Results: Among 118 participants, majority were Malay (72%) males (61%) with a mean age of 49 ± 12.2 years old and prescribed lovastatin (61.9). There was a significant association between statin types (lovastatin and simvastatin) and SAMAE (p = 0.0327); no significant association noted between CK and SAMAE (p = 0.5637). The SLCO1B1 rs4363657 polymorphism was significantly associated SAMAE (p < 0.0001). Conclusions: In this first pilot study of a multiethnic Malaysian population, the incidence of SAMAE was 18.6%. SAMAE were significantly higher in subjects on lovastatin compared to simvastatin. SLCO1B1 rs4363657 polymorphism was a significant risk factor for SAMAE.

中文翻译：

---

一项初步研究关于SLCO1B1 RS4363657基因多态性与刚确诊为他汀类药物的成年新诊断为血脂异常的成年人的肌肉不良事件之间的相关性：马来西亚初级卫生保健队列。

简介：他汀是血脂异常的一线治疗药物，由于其相关的肌肉不良反应，依从性可能欠佳。但是，这些数据仍然有限。目的：确定血脂异常参与者中血清肌酸激酶（CK）和SLCO1B1 rs4363657多态性与他汀类药物相关的肌肉不良事件（SAMAE）的相关性。方法：这是一项政府卫生诊所的前瞻性队列研究，涉及新诊断的成人血脂异常的成年人。在使用他汀类药物一个月后，根据患者的抱怨记录了SAMAE。在基线和随访时进行了CK检查。对SLCO1B1 rs4363657多态性进行了基因分析。结果：在118名参与者中，大多数为马来人（72％）男性（61％），平均年龄为49±12.2岁，并开具洛伐他汀（61.9）。他汀类药物类型（洛伐他汀和辛伐他汀）与SAMAE之间存在显着关联（p = 0.0327）；CK和SAMAE之间无显着相关性（p = 0.5637）。SLCO1B1 rs4363657多态性与SAMAE显着相关（p <0.0001）。结论：在这项针对马来西亚多种族人口的首次试点研究中，SAMAE的发生率为18.6％。与辛伐他汀相比，接受洛伐他汀治疗的受试者的SAMAE显着更高。SLCO1B1 rs4363657多态性是SAMAE的重要危险因素。SAMAE的发生率为18.6％。与辛伐他汀相比，接受洛伐他汀治疗的受试者的SAMAE显着更高。SLCO1B1 rs4363657多态性是SAMAE的重要危险因素。SAMAE的发生率为18.6％。与辛伐他汀相比，接受洛伐他汀治疗的受试者的SAMAE显着更高。SLCO1B1 rs4363657多态性是SAMAE的重要危险因素。